Biocon Limited (BIOCON) Earnings Call Transcripts

Biocon Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Biocon Limited reported a resilient performance with operating revenue growth of 10% year-on-year, driven by a strong biosimilars segment. The company achieved an EBITDA of INR 1,073 crores, translating to a margin of 23%. Management signaled a transition from integration and investment to a focus on execution and profitability, with expectations for continued growth in FY '27, particularly from new product launches in the second half of the year.

Reported metrics

Guidance from management

Management expects to benefit from new product launches in FY '27, particularly in the second half of the year, and aims for continued revenue growth and margin improvement as operating leverage kicks in.

What management said

Yes, Sanjay, the items which go to -- if you're referring to what is captured in the other comprehensive income, there are some adjustments that you do there, which don't appear in the normal P&L. I'll take it offline. Why don't we take it offline Sanjay?

Yes, sorry. So market shares are steady. I think the oncology market shares are steady around 23% to 25%. Glargine market share is also what's reported is about 11% so that's fine. And the next question was in terms of generics margins. We had guided for the fact that from the first quarter till fourth quarter sequentially, as the sales do inch up, there will be a margin improvement. So I think quarter 4, you are s...

What analysts pressed on

Analysts expressed concerns about the stabilization of biosimilars revenue following planned shutdowns and the competitive landscape for new product launches. There were questions regarding the visibility of growth in the generics segment and the impact of new entrants in the insulin market.

Main topics on the call

• Biosimilars Growth — Biosimilars revenue grew 12% year-on-year in Q4 FY '26, driven by strong performance in North America and new product launches. Management stated, "The biosimilars business enters FY '27 on a strong footing with a broade...
• Strategic Integration Completed — Management highlighted the successful integration of biosimilars and generics businesses, completed in under 100 days, which has created a more efficient operating model. Kiran Shaw noted, "We are now operating as one un...
• Financial Performance — For FY '26, adjusted operating revenues and EBITDA grew by 13% and 25% respectively, with EBITDA margin improving to 22%. The reported net profit for the quarter was INR 179 crores, reflecting strong operational leverage...
• Future Product Launches — Management is optimistic about upcoming product launches in FY '27, particularly for biosimilars like aflibercept and insulin Aspart. Shreehas Tambe stated, "You will start seeing that flow through in the second half of ...

Read the full Biocon Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 27 Biocon Limited earnings call transcripts on record, spanning January 24, 2020 to August 6, 2026. Based on this history, Biocon Limited reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIOCON

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Biotechnology

Calls on record

27

First call

January 24, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly